Table 1 Demographics of healthy control subjects

From: CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders

Characteristic

Baseline

Last follow-up

N (% male)

46 (54%)

46 (54%)

Age (year), mean (s.d.)

77 (5)

80 (5)

APOE ɛ4 allele carriers (%)

24%

24%

Education (year), mean (s.d.)

16 (3)

16 (3)

MMSE, mean (s.d.)

29.4 (0·8)

29.0 (1.5)

ADAS-Cog, mean (s.d.)

6.1 (2.9)

6.6 (4.1)

ADAS-MOD, mean (s.d.)

9.3 (3.9)

10.7 (5.8)

CSF Aβ42 (ng l−1), mean (s.d.)

211 (57)

195 (56)

CSF T-tau (ng l−1), mean (s.d.)

73 (30)

83 (30)

CSF P-tau (ng l−1), mean (s.d.)

25 (11)

36 (11)

N with three timepoints

 

23

N with four timepoints

 

23

  1. Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Behavior section; CSF, cerebrospinal fluid; MMSE, mini mental state examination.
  2. CSF Aβ42, T-tau and P-tau calculated using fitted data from linear mixed effect models (adjusted for age, sex, education and APOE) at baseline and 4-year follow-up.
Back to article page